DocDollars

Hikma Pharmaceuticals USA

NJ · United States · Reporting entity ID 100000136575

Total reported 2019–2025
$36.8M
#205 of 2,960 reporting companies — 0% of all reported industry payments
$5.04M in general payments across 26,523 records, plus $31.7M in research funding across 1,224 records.

How it breaks down

General payments $5,041,363
Research funding $31,725,658

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Hikma Pharmaceuticals USA reported $36.8M to US doctors and teaching hospitals from 2019 to 2025, ranking #205 of 2,960 reporting companies. 86% of that was research funding and 14% general payments such as consulting, speaking, food and travel. 26,523 general payment records and 1,224 research records were filed.

Common questions about Hikma Pharmaceuticals USA

How much has Hikma Pharmaceuticals USA paid US doctors?

Hikma Pharmaceuticals USA reported $36,767,022 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $5,041,363 in general payments, $31,725,658 in research funding.

How does Hikma Pharmaceuticals USA rank among drug and device companies?

It ranks #205 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Hikma Pharmaceuticals USA mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.